^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    β-catenin inhibitor

    Related drugs:
    18h
    Adaptive Chemotherapy for the Treatment of Advanced Breast Cancer (clinicaltrials.gov)
    P3, N=192, Recruiting, Sun Yat-sen University | Enrolling by invitation --> Recruiting
    Enrollment status
    |
    gemcitabine • Halaven (eribulin mesylate) • vinorelbine tartrate • utidelone IV (UTD1)
    3d
    OSU-20298: Osimertinib and Tegavivint as First-Line Therapy for the Treatment of Metastatic EGFR-Mutant Non-small Cell Lung Cancer (clinicaltrials.gov)
    P1, N=24, Recruiting, Ohio State University Comprehensive Cancer Center | Trial primary completion date: Jul 2025 --> Jul 2026
    Trial primary completion date
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR L861Q • EGFR G719X • EGFR S768I
    |
    Tagrisso (osimertinib) • tegavivint (BC2059)
    7d
    LEADER: Lenvatinib and Eribulin in Advanced Soft Tissue Sarcoma (clinicaltrials.gov)
    P1/2, N=30, Completed, National Taiwan University Hospital | Active, not recruiting --> Completed | Trial completion date: Dec 2024 --> Oct 2025
    Trial completion • Trial completion date
    |
    Lenvima (lenvatinib) • Halaven (eribulin mesylate)
    21d
    A Phase II Clinical Study of Multimodal Ablation Combined With Systemic Drug Therapy for Advanced Solid Tumors. (clinicaltrials.gov)
    P2, N=95, Recruiting, Fudan University | Not yet recruiting --> Recruiting | Phase classification: PN/A --> P2 | N=66 --> 95 | Trial completion date: May 2028 --> Dec 2028 | Initiation date: Apr 2025 --> Nov 2025 | Trial primary completion date: Jul 2026 --> Dec 2027
    Enrollment open • Phase classification • Enrollment change • Trial completion date • Trial initiation date • Trial primary completion date
    |
    Halaven (eribulin mesylate)
    22d
    ESPERO: Eribulin With or Without Trastuzumab-biosimilar in Patients With HER2-overexpressed Recurrent or Stage IV Breast Cancer (clinicaltrials.gov)
    P2, N=180, Recruiting, Seoul National University Hospital | Trial completion date: Dec 2026 --> Jun 2028 | Trial primary completion date: Dec 2026 --> Jun 2028
    Trial completion date • Trial primary completion date
    |
    HER-2 positive • HER-2 expression
    |
    Halaven (eribulin mesylate) • Ontruzant (trastuzumab-dttb)
    1m
    Predicting the Efficacy of Eribulin in Metastatic Breast Cancer by Assessing E-Cadherin and Vimentin Expression. (PubMed, Acta Histochem Cytochem)
    Altered E-cadherin and/or vimentin expression was more frequently observed in responders (p = 0.013) and associated with longer progression-free survival (p = 0.048). These results suggest that eribulin efficacy may be predicted by altered E-cadherin and vimentin expression before treatment.
    Journal
    |
    CDH1 (Cadherin 1) • VIM (Vimentin)
    |
    Halaven (eribulin mesylate)
    1m
    A Phase Ib Trial of Eribulin in Combination With Irinotecan and Temozolamide in Children With Relapsed or Refractory Solid Tumors (clinicaltrials.gov)
    P1, N=48, Recruiting, M.D. Anderson Cancer Center | Phase classification: P1/2 --> P1
    Phase classification
    |
    temozolomide • irinotecan • Halaven (eribulin mesylate)
    1m
    Targeting Interleukin-6 as a Novel Strategy to Overcome Eribulin Resistance in Breast Cancer. (PubMed, Cancer Med)
    These findings suggest that IL-6 contributes to eribulin resistance in breast cancer and that IL-6 receptor inhibition is a promising therapeutic strategy to overcome this resistance.
    Journal
    |
    IL6 (Interleukin 6)
    |
    doxorubicin hydrochloride • Halaven (eribulin mesylate) • Actemra IV (tocilizumab)
    1m
    Efficacy and Safety of Epalolitovorellizumab in Combination with Eribulin as Second-line and Later-line Therapy for Patients with Advanced Triple-negative Breast Cancer (ChiCTR2500111069)
    P4, N=49, Not yet recruiting, Yantai Yuhuangding Hospital; Yantai Yuhuangding Hospital
    New P4 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative • ER negative
    |
    Halaven (eribulin mesylate)
    2ms
    Zanzalintinib Combined With Eribulin in Advanced Liposarcoma and Leiomyosarcoma (clinicaltrials.gov)
    P1, N=18, Recruiting, Washington University School of Medicine | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Halaven (eribulin mesylate) • zanzalintinib (XL092)
    2ms
    Improved biodistribution and antitumor effects of a Nectin4 and Trop2 bispecific fatty acid-modified nanobody conjugate. (PubMed, J Control Release)
    In nonclinical evaluations, Eribulin-loaded dtNDC demonstrated potent antitumor efficacy across three xenograft models...These findings position dtNDC as a promising therapeutic combining durable tumor regression with exceptional tolerability. Moreover, its simplified structure and cost-effective manufacturing process make this dtNDC a compelling next-generation therapeutic for cancers.
    Journal
    |
    NECTIN4 (Nectin Cell Adhesion Molecule 4)
    |
    Halaven (eribulin mesylate)
    2ms
    A multicenter phase II study of eribulin for BRAF V600E mutant metastatic colorectal cancer: the BRAVERY study (EPOC1701). (PubMed, ESMO Open)
    This phase II study of eribulin for patients with BRAF V600E mutant mCRC did not meet the primary endpoint. Although BM2 on gene expression analysis of BM subtype may be a predictive marker of eribulin efficacy, further studies are required to validate this hypothesis.
    P2 data • Journal
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF V600E • BRAF V600
    |
    Halaven (eribulin mesylate)